News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Gilead Sciences, Inc.
NEWS
JOBS
IN THE PRESS
NEWS
Biotech Bay
Gilead: A Poor Payback Period For Kite Pharma?
September 12, 2017
·
1 min read
Biotech Bay
5 Things Gilead’ Management Just Said That You’ll Want To Know
September 7, 2017
·
1 min read
Deals
How Gilead and Kite Pharma’s Flirtation Became the Real Thing
September 6, 2017
·
3 min read
Biotech Bay
Why Is Gilead On Fire?
September 1, 2017
·
1 min read
Deals
Can Gilead Squeeze $12 Billion From Kite Pharma?
August 30, 2017
·
1 min read
Deals
Why Gilead Could Take Out Juno But Face Major Competition From This Biotech Giant
August 30, 2017
·
2 min read
Deals
Gilead And Kite Pharma. A $12 Billion Deal. One More Pricey Drug.
August 29, 2017
·
1 min read
Business
Gilead Goes Big, Pays $11.9 Billion for This SoCal CAR-T Biopharma
August 28, 2017
·
3 min read
Deals
Why Gilead Might Not Make an Oncology Buy After All
August 16, 2017
·
3 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Business
Gilead Sciences Announces Second Quarter 2018 Dividend
May 1, 2018
·
1 min read
Business
Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
April 30, 2018
·
5 min read
Policy
European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
April 27, 2018
·
3 min read
Biotech Bay
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
April 13, 2018
·
7 min read
Business
Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
March 12, 2018
·
5 min read
Business
National Pharmaceutical Council Welcomes Four Biopharmaceutical Companies as Members
March 6, 2018
·
3 min read
Drug Development
Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen
March 5, 2018
·
9 min read
Drug Development
Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine
March 5, 2018
·
7 min read
Drug Development
Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys
March 4, 2018
·
3 min read
Policy
Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL
February 23, 2018
·
3 min read
